Faron Pharmaceuticals Oy (FARN.L) Stock Analysis & AI Equity Report
Faron Pharmaceuticals Oy (FARN.L) overview
Faron Pharmaceuticals Oy (FARN.L) stock analysis and AI equity research. For the latest completed financial year, 2025, Faron Pharmaceuticals Oy reported revenue of EUR 0m and operating profit of EUR -20.3m; the year-end share price was 180.00 GBP and market capitalisation was GBP 19,364m. Faron Pharmaceuticals Oy is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Faron Pharmaceuticals Oy's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy is a Finland-based clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Its lead program, bexmarilimab, is a novel anti-Clever-1 antibody being studied in combination with standard treatments for hematological cancers and in solid tumors. The company’s value driver is its oncology pipeline and clinical development progress.
Generate the Faron Pharmaceuticals Oy report
Faron Pharmaceuticals Oy is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Faron Pharmaceuticals Oy and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Faron Pharmaceuticals Oy
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.